| Size | Price | |
|---|---|---|
| Other Sizes |
| Targets |
6-Methyluracil does not have a well-defined biological target or receptor. As a nucleobase analog, it can be incorporated into nucleic acids or interact with enzymes involved in pyrimidine metabolism. It may act as a substrate or inhibitor for enzymes such as dihydropyrimidine dehydrogenase or orotate phosphoribosyltransferase. Its lack of a specific receptor target makes it primarily a tool for biochemical and chemical research rather than a drug candidate.
|
|---|---|
| ln Vitro |
In vitro, 6-Methyluracil is used as a precursor or intermediate in chemical synthesis. It is not typically used in cell-based assays to study a specific biological activity. However, as a pyrimidine analog, it can be used to study the specificity of enzymes that recognize uracil or thymine. It may also be used in studies of DNA repair or as a standard in analytical chemistry. Its primary in vitro application is as a chemical reagent.
|
| ln Vivo |
In BALB and SHK mice, 6-methyluracil (50 mg/kg; one intraperitoneal; i.p.) has a strong radioprotective effect[2].
In vivo, 6-Methyluracil has no known therapeutic or biological effects. It is not used for therapeutic purposes. Its primary applications are in chemical synthesis and as a reference standard for analytical purposes. The compound is not intended for human consumption and is for research use only. Comprehensive in vivo pharmacological studies are not available. |
| Enzyme Assay |
For non-cell-based assays, 6-Methyluracil is used as a reference standard and a chemical intermediate. Its identity and purity are confirmed using techniques such as NMR, HPLC, and mass spectrometry. It is not used in receptor binding assays as it is not intended for pharmacological study. Its role is to serve as a building block in organic synthesis and as a standard in analytical method development.
|
| Cell Assay |
For in vitro cellular assays, 6-Methyluracil is not typically used for cell-based functional assays. It may be used in studies of pyrimidine metabolism, where cells are treated with the compound and its effects on nucleotide pools or enzyme activity are measured. However, its primary use is as a chemical reagent rather than a pharmacological tool. The compound's lack of significant biological activity makes it unsuitable for most cell-based assays.
|
| Animal Protocol |
For in vivo animal studies, 6-Methyluracil is not typically used for therapeutic or pharmacological studies. It may be used in metabolic studies where it is administered to animals and its metabolism and distribution are tracked using analytical methods. However, its primary use is as a chemical intermediate rather than a research tool for in vivo studies. The compound is not intended for therapeutic applications in animals.
|
| ADME/Pharmacokinetics |
Metabolism / Metabolites
Following oral administration of 6-methyl-2-thiouracil, rats excreted unchanged 6-methyl-2-thiouracil (46% of the dose), 6-methyluracil (9%), 6-methyl-2-methylthiouracil (2%), 6-methyl-4-oxouracil (2%), 2-amino-6-methyl-4-oxouracil (0.2%), and urea (1%) in their urine. …Studies have shown that 10 ppm bromopyrimidine aqueous solution, after 6 days of irradiation, produces four volatile substances. The major product (37%) is 6-methyluracil. A mixed culture of Pseudomonas and Actinomyces rubrum utilizes 6-methyluracil as the sole carbon and nitrogen source. 6-methyluracil is oxidized to uracil, which is subsequently metabolized into barbituric acid and urea. 6-Methyluracil has a molecular weight of 126.11 g/mol and a molecular formula of C5H6N2O2. It is a white to off-white crystalline powder. The compound is soluble in water and organic solvents. It should be stored at room temperature in a cool, dry place. It is available in high purity (≥97%). It is commonly used as an intermediate in the synthesis of pharmaceuticals, agrochemicals, and other fine chemicals. |
| Toxicity/Toxicokinetics |
Interactions
Inhalation for 5 hours daily for 4 months reduced serum albumin levels and increased serum β-globulin, γ-globulin, and β-lipoprotein levels in rats. During the inhalation period, supplementation of the rat diet with 4-methyluracil normalized lipid and protein metabolism parameters. Prophylactic use of these preparations is recommended among workers in the leather industry. The toxicity profile of 6-Methyluracil has not been extensively reported. As a naturally occurring compound, it is expected to have low toxicity. The compound is not intended for human consumption and is for research use only. Standard safety precautions should be observed when handling the compound, including appropriate personal protective equipment. |
| References | |
| Additional Infomation |
6-Methyluracil is a pyrimidinone, consisting of uracil with a methyl group attached at the 6-position. It is a metabolite functionally related to uracil.
Therapeutic Uses Anti-ulcer drug; radioprotective agent; immunoadjuvant Experimental Applications: Oral administration of 4-methyluracil (50 mg/kg/day) for 3 days before and after laparotomy to rats with lymphatic or hematogenous metastases of Prisley's lymphosarcoma or Walker's carcinosarcoma showed significant anti-metastatic effects. 6-Methyluracil (Pseudothymine, CAS 626-48-2) is a pyrimidine derivative and a methylated analog of uracil. It is a naturally occurring nucleobase analog and is used as a building block in organic synthesis and pharmaceutical research. It serves as a precursor for the synthesis of various biologically active compounds. It is available for research purposes only. |
| Molecular Formula |
C5H6N2O2
|
|---|---|
| Molecular Weight |
126.11
|
| Exact Mass |
126.042
|
| CAS # |
626-48-2
|
| PubChem CID |
12283
|
| Appearance |
White to off-white solid powder
|
| Density |
1.2±0.1 g/cm3
|
| Melting Point |
318 °C (dec.)(lit.)
|
| Flash Point |
208ºC
|
| Index of Refraction |
1.490
|
| LogP |
-0.12
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
2
|
| Rotatable Bond Count |
0
|
| Heavy Atom Count |
9
|
| Complexity |
195
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
CC1=CC(=O)NC(=O)N1
|
| InChi Key |
SHVCSCWHWMSGTE-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C5H6N2O2/c1-3-2-4(8)7-5(9)6-3/h2H,1H3,(H2,6,7,8,9)
|
| Chemical Name |
6-methyl-1H-pyrimidine-2,4-dione
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO: 50 mg/mL (396.48 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 4.55 mg/mL (36.08 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 45.5 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (19.82 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (19.82 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 7.9296 mL | 39.6479 mL | 79.2959 mL | |
| 5 mM | 1.5859 mL | 7.9296 mL | 15.8592 mL | |
| 10 mM | 0.7930 mL | 3.9648 mL | 7.9296 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
